{"id":58684,"date":"2016-01-04T18:54:41","date_gmt":"2016-01-04T23:54:41","guid":{"rendered":"https:\/\/rarediseases.org\/fda-approves-21-orphan-drugs-for-rare-diseases-in-2015-sets-record-for-second-consecutive-year\/"},"modified":"2016-01-04T18:54:41","modified_gmt":"2016-01-04T23:54:41","slug":"fda-approves-21-orphan-drugs-for-rare-diseases-in-2015-sets-record-for-second-consecutive-year","status":"publish","type":"post","link":"https:\/\/rarediseases.org\/es\/fda-approves-21-orphan-drugs-for-rare-diseases-in-2015-sets-record-for-second-consecutive-year\/","title":{"rendered":"FDA Approves 21 Orphan Drugs for Rare Diseases in 2015, Sets Record for Second Consecutive Year"},"content":{"rendered":"

\"fda\"<\/a>The U.S. Food and Drug Administration announced<\/a> today it approved 21 new orphan drugs to treat rare diseases in 2015, nearly half (47 percent) of all novel new drugs approved for the year.\u00a0 This is the second consecutive year in which the FDA approved more orphan drugs for rare diseases than any previous year in FDA history, according to John K. Jenkins, M.D., Director, Office of New Drugs, Center for Drug Evaluation and Research at FDA.<\/p>\n

\u201cThe remarkable number of\u00a0orphan\u00a0drugs\u00a0approved\u00a0by FDA in 2015 underscores the progress we are making in identifying and studying new therapies, the willingness of the investment community to invest in\u00a0orphan\u00a0drugs, and the continued flexibility shown by the FDA in reviewing applications that often include small studies due to the small number of patients with the disease,\u201d said Peter L. Saltonstall, president and CEO of the National Organization for Rare Disorders (NORD), the primary independent nonprofit organization representing all patients and families affected by rare diseases in the U.S.<\/p>\n

Saltonstall added, \u201cAt the same time, we must recognize that our patient community faces new challenges in accessing many new therapies, and that the vast majority of the 7,000 identified rare diseases still have no treatment options.\u201d<\/p>\n

\u201cNORD has been the leading advocate for the rare disease community for more than three decades.\u00a0 The progress reflected in so many new therapies re-energizes all of us who are dedicated to improving the lives of people with rare diseases.\u00a0 We look forward to still more approvals in 2016 and beyond,\u201d Saltonstall concluded.<\/p>\n

For more details about 2015\u2019s approvals, visit the Novel New Drugs Summary 2015.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The U.S. Food and Drug Administration announced today it approved 21 new orphan drugs to treat rare diseases in 2015, nearly half (47 percent) of all novel new drugs approved … <\/p>\n

Continue reading “FDA Approves 21 Orphan Drugs for Rare Diseases in 2015, Sets Record for Second Consecutive Year”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[232,504],"tags":[657,244,927,653,262,263,243,928],"class_list":["post-58684","post","type-post","status-publish","format-standard","hentry","category-advocacy","category-press-releases","tag-center-for-drug-evaluation-and-research","tag-fda","tag-john-k-jenkins","tag-office-of-new-drugs","tag-orphan-drug-act","tag-orphan-drugs","tag-peter-l-saltonstall","tag-press-release"],"acf":[],"_links":{"self":[{"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/posts\/58684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/comments?post=58684"}],"version-history":[{"count":0,"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/posts\/58684\/revisions"}],"wp:attachment":[{"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/media?parent=58684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/categories?post=58684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/tags?post=58684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}